Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Is a Beat Likely for Moderna (MRNA) This Earnings Season?
by Zacks Equity Research
Investors are likely to focus on any updated outlook for Moderna's (MRNA) authorized coronavirus vaccine, on the second-quarter earrings call.
Corcept's (CORT) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Corcept (CORT) beats on both earnings and revenues in the second quarter of 2021. The company maintains the revenue guidance for 2021.
Pharma Stock Roundup: Q2 Earnings of MRK, PFE & Others, FDA Approvals for GSK, ABBV
by Kinjel Shah
Pfizer (PFE), Merck (MRK) and others announce Q2 results. FDA approves AbbVie's (ABBV) new antibiotic injection and expands use of Merck's Keytruda and Glaxo's Shingrix and Nucala.
Pharma & Healthcare ETFs at a One-Year High: Here's Why
by Sanghamitra Saha
Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.
Glaxo's (GSK) Q2 Earnings Beat, Revenues on Recovery Track
by Zacks Equity Research
Glaxo's (GSK) revenues benefit from recovery in sales of products across all segments and additional revenues from the supply of pandemic adjuvant to partners.
Stock Market News for Jul 29, 2021
by Zacks Equity Research
U.S. stock markets closed mixed on Wednesday following the Fed's decision to keep interest rate near zero.
Bristol-Myers' (BMY) Q2 Earnings Beat, Opdivo Sales Grow
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the second quarter as Opdivo sales revive.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
Trade Numbers Sink Near Record, Q2 Earnings Beats for PFE, BA & MCD
by Mark Vickery
Boeing (BA) posted a surprise profit in Q2, and shares are up over 5% in pre-market trading as a result.
Pfizer (PFE) Q2 Earnings Beat, View Up on COVID-19 Vaccine
by Zacks Equity Research
Pfizer (PFE) beats second-quarter estimates for earnings and sales. It lifts its guidance for 2021.
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Pfizer (PFE) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 10.31% and 8.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Pfizer (PFE)
by Zacks Equity Research
Pfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat Likely for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
AbbVie's (ABBV) second-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on any update related to guidance.
Gilead (GILD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports second-quarter 2021 results.
Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY
by Zacks Equity Research
Let us take a look at five drug/biotech companies - PFE, GSK, BMY, BMRN and TLRY - which are gearing up for their earnings release.
Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2021 results.
Merck (MRK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.
Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Vaxart's (VXRT) second-quarter earnings call, investors are set to mainly focus on updates on the company's progress with oral vaccine candidates for COVID-19 and Norovirus.
What's in the Cards for AstraZeneca (AZN) in Q2 Earnings?
by Zacks Equity Research
AstraZeneca's (AZN) second-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on an updated guidance after Alexion acquisition.
Arvinas (ARVN), Pfizer Team up for Breast Cancer Therapy
by Zacks Equity Research
Arvinas (ARVN) collaborates with Pfizer for its investigational breast cancer candidate, ARV-471. Pfizer is also set to acquire an equity stake in Arvinas. The stock rises 9% post the announcement.
Will Pfizer (PFE) Beat Expectations This Earnings Season?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the second quarter.
Glaxo (GSK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven second-quarter sales. However, sales of vaccines are likely to have been hurt by COVID-19 vaccine prioritization.
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, PFE, ABBV, LLY & MRK FDA Updates
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.
Will Teladoc (TDOC) Q2 Earnings Show Weak Telehealth Demand?
by Zacks Equity Research
Teladoc's (TDOC) Q2 results are likely to reflect a rise in revenues but overall tepid demand as patients started visiting doctors' clinics for in-person checkups.